Am J Drug Deliv 2004; 2 (4): 1

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1. Theoretical Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 2. Biopharmaceutics Classification System . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3. Cyclodextrins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 3.1 Cyclodextrin Complexes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 3.2 Cyclodextrins and Drug Permeability Through Biologic Membranes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 4. Cyclodextrins in Immediate-Release Oral Dosage Forms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 4.1 Class I Drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 4.2 Class II Drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 4.3 Class III Drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 4.4 Class IV Drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 5. Cyclodextrins in Buccal, Sublingual, and Modified-Release Formulations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 6. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 The use of high-throughput screening and similar techniques in drug discovery has put a number of Abstract evolutionary pressures on drug candidates such that over time there is a tendency for them to increase in molecular weight, increase in log K(octanol/water) and decrease in water solubility. These trends provide an ever-increasing series of challenges for the drug formulator to generate effective, orally bioavailable dosage forms. An important tool in this regard is the use of cyclodextrins, especially chemically modified cyclodextrins. These starch derivatives interact via dynamic complex formation and other mechanisms in a way that camouflages undesirable physicochemical properties, including low aqueous solubility, poor dissolution rate and limited drug stability. Through these effects, cyclodextrins and their derivatives have become popular modalities for increasing oral bioavailability and absorption rate. These actions have positioned cyclodextrins as important enabling and functional excipients. This review aims to assess the use of cyclodextrins in oral and other administration routes in the context of the Biopharmaceutical Classification Systems (BCS), a US FDA-based characterization approach that bins drugs based on solubility and permeability features. Specifically, a framework based on Fickian theory as well as the Noyes-Whiney relationship is constructed to assess where cyclodextrins are likely to be useful and where their use is probably not justified. This working model is examined in the context of a number of published examples in which cyclodextrins have been applied to class I, II, III, and IV drugs and drug candidates. Oral drug administration is the preferred route of drug delivery sive, and patient friendly. Systemic drug absorption from, for and solid oral dosage forms are the most common drug formulaexample, immediate-release tablets, consists of a series of rate tions. Conventional tablets are relatively easy to produce, inexpenprocesses: A U T H O R P R O O F 2 Loftsson et al. Disintegration Dissolution Permeation Partition Permeation Tablet Solid drug particles Drug solution Unstirred aqueous layer Mucosa The general blood circulation